Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U.
Urup T, et al. Among authors: broholm h.
Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26.
Mol Oncol. 2016.
PMID: 27262894
Free PMC article.